Member Info for Marty130

Let's hope the loses are lower than last year..

Https://fintel.io/s/gb/apta

3

The 12-month price target for Aptamer Group PLC (APTA) is approximately 183.60 GBX, with forecasts ranging from 181.80 to 189.00 GBX. This target is based on analyst ratings, which currently show a "Buy" consensus recommendation. The current market price is around 1.05 GBX as of October 11, 2025.

Are we witnessing a company finally finding its feet, with more deals to be struck in the coming months.

U2

For a while now, so I decided to on this brilliant news to invest. Onwards and upwards.

Filleted...

Https://www.sec.gov/enforcement-litigation/litigation-releases/lr-25366

Ronald Bauer Led a Sophisticated Conspiracy to Defraud Investors Around the World

The United States Attorney for the Southern District of New York announced today that RONALD BAUER was sentenced to 20 months in prison for manipulating seven different stocks in a “pump-and-dump” scheme designed to fraudulently inflate the value of BAUER’s own shares in those companies. BAUER pled guilty on November 4, 2024, before U.S. District Judge Paul A. Engelmayer, who imposed today’s sentence.

Why would you say that? People taking a risk with their hard earned,.sometimes paying off in millions, as I have witnessed personally by people who know this market very well..

Nothing... AIM stocks way too risky to short.

Good luck to everyone.

I am down 1.5%, at currant price levels.

Hopefully.

Correct, sorry, my mistake.

From X

The Genflow Biosciences team has decades of experience in the biotechnology and pharmaceutical sectors.

Our team has worked with highly reputable institutions ranging from GSK, Pfizer and Schering Plough to world class universities such as Harvard, Oxford, LSE and UCL.

Renalytix PLC (AIM:RENX) has announced a $4 million balance sheet improvement, following the conversion of senior convertible bonds into equity.

Some 31.6 million new ordinary shares will be issued at 9.5p per share.

The bondholder, advised by Heights Capital Ireland, will receive shares equivalent to the outstanding bond value.

The transaction is expected to save Renalytix up to $1.4 million in accrued interest and strengthen its debt-to-equity ratio. The new shares will be admitted to trading on AIM on 15 October.

Renalytix shares rose by 2.2% changing hands at 9.2p.

Your not far out, with some analysts projecting 86p in a year from July 2025.

Https://genflowbio.com/genflow-biosciences-ceo-welcomes-new-investment-outlines-dog-longevity-trial/

What values are we talking about, in reference to selling part of their assets.